Compare Manhattan Associates Inc (MANH) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Manhattan Associates Inc vs Nuwellis Inc — how do they compare? Manhattan Associates Inc trades at $204.05 (market cap $12.06B), while Nuwellis Inc trades at $0.68 (market cap $2.20M). The key difference: Manhattan Associates Inc is far larger — about 5481.8× Nuwellis Inc's market cap, and Manhattan Associates Inc is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Manhattan Associates Inc for 12 Days and Nuwellis Inc for 26 Days on average.
| MANH | NUWE | |
|---|---|---|
Market Cap | $12.06B | $2.20M |
Volume | 376,150 | 121,544 |
Sector | Technology | Health |
52-Week High | $223.76 | $146.65 |
52-Week Low | $120.88 | $0.68 |
Typical Hold Time | 12 Days | 26 Days |
Enterprise Value | $11.93B | -$1.52M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MANH trades at $205.29, up 1.57% with strong technical momentum and bullish moving average signals. The company demonstrates robust profitability with 18.67% net margins and consistent earnings beats, though valuation metrics remain elevated. Recent news includes product expansion with Editions launch and ongoing legal investigations regarding fiduciary duties.
Outlook remains positive with analyst consensus at Buy and $210.50 target, though risks include high valuation multiples and legal scrutiny. The stock offers growth potential through strong operational performance but faces headwinds from potential governance concerns and competitive pressures in the software sector.
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Manhattan Associates Inc
Manhattan Associates, Inc. is a global leader in supply chain and omnichannel commerce software. The company provides a comprehensive suite of cloud-based and on-premise solutions for warehouse management (WMS), transportation management (TMS), and order management (OMS). MANH's technology helps retailers, wholesalers, and manufacturers manage inventory, optimize logistics, and unify the shopping experience across physical and digital channels.
Read more on MANH →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
